[Huatai] Ssangyong shares: Dingzeng wants to acquire Wellcome Pharmaceuticals, transforming medicine continues to increase its size.
Ssangyong shares (300108): Dingzeng wants to acquire Wellcome Pharmaceutical Transformation Pharmaceutical and continue to increase its size.
[Huatai] Ssangyong shares: 15 years is the first year of transition medicine breakthrough
[national Securities] Ssangyong shares: the performance is in line with expectations, and the sales expenses have dropped greatly.
[Huatai] Ssangyong shares: the transformation of medicine has achieved results, and a breakthrough in 15 years is imminent.
[Changjiang Securities] Ssangyong shares: and show a substantial improvement in performance, the right time to transform medicine
[Huatai] Ssangyong shares: there has been a slight increase in the main business, and the profit of Jinbao has greatly increased.
[Anxin Securities] Ssangyong shares: merger and acquisition of Jilin Jinbao Pharmaceutical, Chemical and Pharmaceutical two-wheel Drive
Ssangyong (300108): merger and acquisition of Jilin Jinbao Pharmaceutical Chemical and Pharmaceutical two-wheel Drive
Ssangyong (300108): the performance is in line with the expected green tire specification will be issued.
【安信证券】双龙股份:业绩符合预期,绿色轮胎规范将出台
【安信证券】双龙股份:需求下滑,业绩略低于预期
双龙股份(300108)季报点评:需求下滑 业绩略低于预期
双龙股份(300108)中报点评:业绩环比好转显著
双龙股份(300108)一季报点评:业绩环比将逐渐好转
【安信证券】双龙股份:业绩环比将逐渐好转
【安信证券】双龙股份:业绩基本符合预期
双龙股份(300108)年报点评:业绩基本符合预期
【安信证券】双龙股份:毛利率上升,业绩稳定增长
【安信证券】双龙股份2012年一季报点评:业绩将逐步兑现
No Data